{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:58:48Z","timestamp":1790427528807,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.urolonc.2026.08.027","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:17:36Z","timestamp":1790425056000},"page":"939-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Recep","family":"Ery\u0131lmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Fatih","family":"Kele\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmi","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00fcbeyir","family":"Huyut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kas\u0131m","family":"Erta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-1075","authenticated-orcid":false,"given":"Mehmet","family":"Sevim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"Taken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.urolonc.2026.08.027_bib0001","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.08.027_bib0002","unstructured":"Babjuk M, Burger M, Comp\u00e9rat E, Gontero P, Mostafid A, Palou J, EAU guidelines. Edn presented at the EAU annual congress milan; 2020."},{"key":"10.1016\/j.urolonc.2026.08.027_bib0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.urology.2019.01.011","article-title":"The prevalence of bladder cancer during cystoscopy for asymptomatic microscopic hematuria","volume":"126","author":"Gonzalez","year":"2019","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.027_bib0004","doi-asserted-by":"crossref","first-page":"27.e1","DOI":"10.1016\/j.urolonc.2012.09.011","article-title":"Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer","volume":"32","author":"Yafi","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.08.027_bib0005","doi-asserted-by":"crossref","unstructured":"Klyosov AA, Witczak ZJ, Platt D. editors. Galectins. Hoboken, NJ: Wiley; 2008. p. 1\u20138. https:\/\/doi.org\/10.1002\/9780470378076.ch1.","DOI":"10.1002\/9780470378076"},{"issue":"9","key":"10.1016\/j.urolonc.2026.08.027_bib0006","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bbagen.2011.11.014","article-title":"Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages","volume":"1820","author":"Novak","year":"2012","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.027_bib0007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","article-title":"Galectin-3\u2013a jack-of-all-trades in cancer","volume":"313","author":"Newlaczyl","year":"2011","journal-title":"Cancer Letters"},{"issue":"9269","key":"10.1016\/j.urolonc.2026.08.027_bib0008","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(00)04817-0","article-title":"Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions","volume":"357","author":"Bartolazzi","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.027_bib0009","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/glycob\/cwy001","article-title":"Galectin-3 and cancer stemness","volume":"28","author":"Nangia-Makker","year":"2018","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.027_bib0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-018-0668-y","article-title":"Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.027_bib0011","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13277-010-0033-9","article-title":"Galectin-3 expression is associated with bladder cancer progression and clinical outcome","volume":"31","author":"Canesin","year":"2010","journal-title":"Tumor Biol"},{"issue":"1, 2","key":"10.1016\/j.urolonc.2026.08.027_bib0012","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2152\/jmi.55.127","article-title":"Serum level of galectin-3 in human bladder cancer","volume":"55","author":"Sakaki","year":"2008","journal-title":"J Med Investig"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.027_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.21037\/tau-22-494","article-title":"Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer","volume":"12","author":"Zhu","year":"2023","journal-title":"Transl Androl Urol"},{"issue":"20","key":"10.1016\/j.urolonc.2026.08.027_bib0014","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3390\/diagnostics14202270","article-title":"Is immunohistochemical galectin-3 expression associated with the epithelial\u2013mesenchymal transition in high-and low-grade invasive urothelial carcinomas of the bladder?","volume":"14","author":"Cin","year":"2024","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.027_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00432-008-0481-4","article-title":"Galectin-3 in urine of cancer patients: stage and tissue specificity","volume":"135","author":"Balasubramanian","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.08.027_bib0016","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","article-title":"An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.027_bib0017","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.027_bib0018","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.08.027_bib0019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000365673","article-title":"Diagnostic and prognostic significance of serum and tissue galectin 3 expression in patients with carcinoma of the bladder","volume":"7","author":"Gendy","year":"2014","journal-title":"Curr Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:17:40Z","timestamp":1790425060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1078143926007283"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.027","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}